Emergent BioSolutions Inc. (EBS) financial statements and ratios from SEC XBRL: revenue $742.90M (TTM), net margin 7.1%, revenue growth -28.8% YoY, P/E 2.3. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $742.90M |
| Net Margin | 7.1% |
| Revenue Growth (YoY) | -28.8% |
| EPS Growth (YoY) | -127.2% |
| FCF Growth (YoY) | 338.0% |
| P/E Ratio | 2.3 |
| EV / EBITDA | 3.3 |
| Price / Book | 0.50 |
| Price / Sales | 0.35 |
| FCF Yield | 46.0% |
| Altman Z-Score | 1.33 (distress) |
| Piotroski F-Score | 8/9 |
| Sector P/E (Healthcare) | 21.7 |
EBS overview · EBS earnings · EBS KPIs · EBS investor relations · EBS ownership · EBS peers · EBS filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.